Absci.com
Biologics Drug Discovery Absci
WEBAbsci enables a shift from drug discovery to drug creation. We unlock new possibilities in de novo design, lead optimization, target identification, and antibody-drug conjugate (ADC) development, where drugmakers seek candidates with tailored target binding, better manufacturability, lower immunogenicity, and shorter development times. By enabling …
Actived: 2 days ago
Our Biologics Pipeline Absci
WEBAbsci’s biologics pipeline reflects our differentiated capabilities in de novo antibody creation, multiparameter lead optimization, and reverse immunology. We’re developing a diversified portfolio of programs with a focus on cytokine biology as we scale our drug creation platform and strive to impact millions of lives.
Almirall and Absci announce AI drug discovery partnership to …
WEBThe collaboration expands Absci’s de novo AI drug creation portfolio into dermatology and accelerates discovery for broader chronic inflammatory diseases VANCOUVER, Wash. and BARCELONA, Spain, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI ), a generative AI drug creation
Programming E. coli to outsmart disease Absci
WEBAbsci’s roots are in cell line development, and a decade of work produced SoluPro, its E. coli platform with a semi-oxidized cytoplasm that enables the production of complex, disulfide-bonded proteins while maintaining a healthy cell population at commercial scales. SoluPro offers advantages over CHO mammalian systems by …
Absci to Participate in the BTIG MedTech, Digital Health, Life …
WEBVANCOUVER, Wash., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the company will be participating virtually in the upcoming BTIG MedTech, Digital Health, Life Science & …
News Release Details
WEBVANCOUVER, Wash., March 01, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced that Sean McClain, CEO & Founder, will be participating on the Synthetic Biology Enabling Drug …
Absci First to Create and Validate De Novo Antibodies with Zero …
WEBThis breakthrough unlocks the potential to accelerate time to clinic by over 50% and increase probability of success in the clinic. Creating antibodies in silico with generative AI represents a major industry breakthrough on the path to fully de novo antibody design and Absci’s vision to deliver breakthrough therapeutics at the click of a …
St. John’s Cancer Institute Partners with Absci to Expedite …
WEBSince its affiliation with Saint John’s Health Center over 30 years ago, the institute combines the exceptional quality of Saint John’s medical staff and hospital with translational research, fellowships, and extensive global collaboration. Leading the remarkable charge of the institute founder, the late Donald L. Morton, M.D., whose
Absci Announces Collaboration with AstraZeneca to Advance AI …
WEBCollaboration Combines Absci’s AI Antibody Drug Creation Platform with AstraZeneca’s Expertise in Oncology Research and Development. VANCOUVER, Wash., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a leader in generative AI antibody discovery, today announced a collaboration with AstraZeneca, a …
Absci and Caltech Join Forces, Bolstered by Major Grant, to …
WEBAbsci and Caltech Join Forces, Bolstered by Major Grant, to Accelerate Affordable HIV Therapeutic Vaccine Development. Aug 10, 2023. Vancouver, WA (Aug 10, 2023) — Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced that leading researchers at the California Institute of Technology (Caltech) in …
Absci Reports Business Updates and Third Quarter 2023 Financial …
WEBThird Quarter 2023 Financial Results. Revenue was $0.7 million for the three months ended September 30, 2023 compared to $2.4 million for the three months ended September 30, 2022. This decrease was driven by partnered program mix and progress timing. Research and development expenses were $11.0 million for the third quarter of 2023 compared to
AbSci Announces Strategic Investment by Merck Global Health …
WEBFeb 22, 2021. VANCOUVER, Wash., – February 22, 2021 – AbSci, a pioneering synthetic biology company that unifies biologic drug discovery and development processes, today announced a strategic equity investment by Merck Global Health Innovation Fund (Merck GHI) and potential discovery collaborations with Merck Research Laboratories.
Investor Relations Absci Corp
WEBVANCOUVER, Wash. and NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming 23 rd Annual Needham Virtual Healthcare Conference. Initiated IND-enabling studies for ABS-101, a …
From idea to impact: Creating drugs that matter Absci
WEBAddressing health inequalities is chief among them. For example, as shared in Harvard Health, 70% of those affected by chronic pain conditions are women, whereas 80% of pain research is conducted on males. Other studies show that resources are often disproportionately allocated to diseases primarily affecting men.
Absci to Participate in the 43rd Annual Cowen Health Care …
WEBVANCOUVER, Wash. and NEW YORK, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcoming 43 rd Annual Cowen Health Care Conference. Absci’s management is scheduled to participate in a panel …
Integrated Drug Discovery Partnerships Absci
WEBDe-risk your biologics drug discovery pipeline. Absci enables our partners to explore the broadest possible solution space faster than conventional methods. Our multi-parameter optimization approach tunes affinity, specificity, manufacturability, and safety all at once. Our Integrated Drug Creation™ platform gives drug makers new potential:
41st Annual J.P. Morgan Healthcare Conference Absci
WEBJan 09-12, 2023. Join us at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA. January 9-12, 2023. Watch our presentation on Tuesday, January 10 th at 5:15 p.m. Pacific Time (8:15 p.m. Eastern Time). This presentation time has been updated from a previous announcement and reflects the current schedule.
Absci Evolves its Board of Directors with HealthTech Luminary …
WEBAbsci announced the appointment of Frans van Houten to its Board of Directors. With his exceptional leadership experience and deep industry knowledge in the healthcare and technology industries, van Houten will play a pivotal role in supporting Absci’s strategic vision and growth trajectory.
Top Categories
Popular Searched
› How has healthcare been changed
› Ewg healthy living working group
› Healthy breakfast ideas for mama
› Valley health lab rock cliff wv
› Connection health care staffing
› Healthy minds online therapy
› Benefits of connected health
› Healthy breakfast ideas for couples
Recently Searched
› University of kansas health building
› Advent health redmond regional medical center
› My health chart atlantic health
› Peach tree health marysville ca
› Kansas health foundation impact grants
› Northern beaches mental health conferences
› Northern az health care patient portal
› Data quality improvement in healthcare
› Mental health matters coventry